title: Reply to T.J. Kruser et al.
authors.affiliation: Aix-Marseille University, AP-HM, Centre Hospitalier Universitaire Timone, Marseille, France olivier.chinot@ap-hm.fr.
authors.forename: Olivier L
authors.initials: OL
authors.lastname: Chinot
authors.affiliation: Medical Center Haaglanden, The Hague, and VU University Medical Center, Amsterdam, the Netherlands.
authors.forename: Martin J B
authors.initials: MJ
authors.lastname: Taphoorn
authors.affiliation: Genentech, South San Francisco, CA.
authors.forename: Carlos
authors.initials: C
authors.lastname: Bais
authors.affiliation: Genentech, South San Francisco, CA.
authors.forename: Richard
authors.initials: R
authors.lastname: Bourgon
authors.affiliation: Genentech, South San Francisco, CA.
authors.forename: Heidi S
authors.initials: HS
authors.lastname: Phillips
authors.affiliation: F. Hoffmann-La Roche, Basel, Switzerland.
authors.forename: Lauren E
authors.initials: LE
authors.lastname: Abrey
authors.affiliation: University Medical Center, Heidelberg, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.affiliation: Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: Warren
authors.initials: W
authors.lastname: Mason
authors.affiliation: Regional Cancer Center Stockholm, Stockholm, and Umeå University, Umeå, Sweden.
authors.forename: Roger
authors.initials: R
authors.lastname: Henriksson
authors.affiliation: The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.
authors.forename: Frank
authors.initials: F
authors.lastname: Saran
authors.affiliation: Saitama Medical University, Saitama, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Nishikawa
authors.affiliation: University of California, Los Angeles, Los Angeles, CA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Cloughesy
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000628:therapy*; D059248:Chemoradiotherapy; D003606:Dacarbazine / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D008297:Male; D011788:Quality of Life
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine